Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

(2019) Myriam Alexander et al.   BMC Medicine

GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH

(2019) Zobair Younossi et al.   JOURNAL OF HEPATOLOGY

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

(2018) Chris Estes et al.   JOURNAL OF HEPATOLOGY

Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany

(2018) Christian Labenz et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation

(2018) Yvonne Huber et al.   Clinical Gastroenterology and Hepatology

Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease

(2018) Fasiha Kanwal et al.   GASTROENTEROLOGY

Non-alcoholic fatty liver disease – A global public health perspective

(2018) Zobair M. Younossi   JOURNAL OF HEPATOLOGY

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

(2017) Hannes Hagström et al.   JOURNAL OF HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score and the Risk of Incident Diabetes in a Korean population

(2013) Yoosoo Chang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY